MAXCYTE, INC.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

MXCT$1.13-13.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

Unaudited Condensed Consolidated Statements of Operations** and Comprehensive Loss**

(in thousands, except share and per share amounts)


· · Three Months Ended September 30, · · Nine Months Ended September 30,
· · 2026 · · 2025 · · 2026 · · 2025
Revenue	$10,152	$6,829	$27,074	$25,726
Cost of goods sold	1,684	1,596	4,928	4,612
Gross profit	8,468	5,233	22,146	21,114

Operating expenses:
Research and development	2,874	5,316	10,984	17,488
Sales and marketing	4,214	3,936	11,006	15,420
General and administrative	6,553	6,028	19,777	22,634
Restructuring expense	—	3,058	—	3,058
Depreciation and amortization	868	1,044	2,837	3,185
Total operating expenses	14,509	19,382	44,604	61,785
Operating loss	(6,041)	(14,149)	(22,458)	(40,671)

Other income:
Interest income	1,279	1,733	4,072	5,637
Total other income	1,279	1,733	4,072	5,637
Loss before income taxes	(4,762)	(12,416)	(18,386)	(35,034)
Provision for income taxes	—	—	—	—
Net loss	(4,762)	(12,416)	(18,386)	(35,034)
Other comprehensive income	—	—	—	—
Comprehensive loss	$(4,762)	$(12,416)	$(18,386)	$(35,034)
Basic and diluted net loss per share	$(0.05)	$(0.12)	$(0.17)	$(0.33)
Weighted-average shares outstanding, basic and diluted	103,537,926	106,613,075	105,732,991	106,324,792

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.